LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

LLY

724.64

-0.01%↓

JNJ

181.13

+0.83%↑

ABBV

221.21

+0.22%↑

UNH

344.46

+0.09%↑

NVO

55.48

-0.22%↓

Strona główna・Stock List・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Open

4.44 0.91

Buy Sell

Overview

Share price change

24h

Current

Min

4.36

Max

4.46

Key metrics
By Trading Economics
Income	27M 2.5M
Sales	9M 11M
Profit margin	23.494
Employees	44
EBITDA	27M 2.6M

Market Stats
By TradingEconomics
Market Cap	210M 849M
Previous open	3.53
Previous close	4.44

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

3.255 / 3.365 Support & Resistance

Arbutus Biopharma Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 wrz 2025, 18:25 UTC

Major Market Movers

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

28 wrz 2025, 23:48 UTC

Market Talk

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

28 wrz 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 wrz 2025, 23:45 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

28 wrz 2025, 23:34 UTC

Market Talk

Oil Falls on Likely Technical Correction -- Market Talk

27 wrz 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26 wrz 2025, 20:54 UTC

Earnings

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26 wrz 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 wrz 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26 wrz 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26 wrz 2025, 19:53 UTC

Acquisitions, Mergers, Takeovers

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26 wrz 2025, 19:40 UTC

Earnings

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26 wrz 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26 wrz 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26 wrz 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26 wrz 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26 wrz 2025, 18:50 UTC

Market Talk

Earnings

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26 wrz 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: Global Development Hasn't Received All Necessary Approvals >ING

26 wrz 2025, 18:02 UTC

Acquisitions, Mergers, Takeovers

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26 wrz 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26 wrz 2025, 16:56 UTC

Market Talk

Earnings

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26 wrz 2025, 16:41 UTC

Market Talk

Earnings

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26 wrz 2025, 16:26 UTC

Earnings

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26 wrz 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Arbutus Biopharma Corp - Dist in the past 3 months.

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.